<DOC>
	<DOCNO>NCT00353496</DOCNO>
	<brief_summary>The study compare difference lanreotide Autogel placebo progression free survival patient endocrine tumour pancreas intestine .</brief_summary>
	<brief_title>Study Lanreotide Autogel Non-functioning Entero-pancreatic Endocrine Tumours</brief_title>
	<detailed_description />
	<mesh_term>Endocrine Gland Neoplasms</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Endocrine tumour intestine pancreas locally advance metastatic disease No hormone relate symptom Well moderately differentiate tumour confirm histology Tumour lesion measurable CT MRI scan Previously treat somatostatin analogue unless 6 month ago give 15 day Treated within last 6 month interferon , chemoembolisation chemotherapy time radionuclide Had previous cancer except basal cell carcinoma and/or situ carcinoma cervix/uterus and/or patient treat curative intent free disease 5 year Pregnant lactating Females must use adequate contraception study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Non function entero-pancreatic tumour</keyword>
</DOC>